Biodesix, Inc.
2970 Wilderness Place
Suite 100
Boulder
Colorado
80301
United States
Tel: 303-417-0500
Website: http://www.biodesix.com/
Email: info@biodesix.com
205 articles about Biodesix, Inc.
-
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
4/9/2024
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
-
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
4/5/2024
Biodesix, Inc. today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share.
-
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
3/25/2024
Biodesix, Inc. announced that it has entered into a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.
-
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
3/1/2024
Biodesix, Inc. provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023.
-
Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
2/26/2024
Biodesix, Inc. announced that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be held from March 4-6, 2024.
-
Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
2/16/2024
Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1.
-
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method
11/14/2023
Biodesix, Inc. announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing.
-
Biodesix to Participate in Two Upcoming Investor Conferences in November 2023
11/9/2023
Biodesix, Inc. announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences.
-
Biodesix Announces Third Quarter 2023 Results and Highlights
11/7/2023
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update.
-
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
10/24/2023
Biodesix, Inc., a leading diagnostic solutions company with a focus on lung disease, announced that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7.
-
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
10/3/2023
Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.
-
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
9/7/2023
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that two abstracts will be presented at the International Association for the Study of Lung Cancer 2023 World Lung Conference on Lung Cancer.
-
Biodesix to Participate in Two Upcoming Investor Conferences in September 2023
9/5/2023
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences.
-
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
8/22/2023
Biodesix, Inc. announced that a new analysis from the post-market, prospective, real-world ORACLE study will be presented at the 6th Annual Conference of the American Association for Bronchology and Interventional Pulmonology.
-
Biodesix Announces Second Quarter 2023 Results and Highlights
8/7/2023
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update.
-
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
8/1/2023
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, which will be held from August 7-10, 2023.
-
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
7/24/2023
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus on lung disease, announced that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7.
-
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
7/12/2023
Biodesix, Inc. announced that the prospective, real-world ORACLE study achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures.
-
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
7/6/2023
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT ® Test by the Center for Medicare and Medicaid Services BOULDER, Colo.--( BUSINESS WIRE )-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has designated the Nodify CDT ® Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023. Obtaini
-
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
6/27/2023
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that the large multi-center observational registry study INSIGHT has completed enrollment of 5,000 patients with non-small cell lung cancer.